INTRODUCTION — Acute kidney injury (AKI) may develop after administration of iodinated contrast material [1-11]. AKI that is judged to be caused by iodinated contrast material (ie, after exclusion of other possible etiologies) has historically been called contrast-induced nephropathy (CIN) but has since been termed contrast-induced AKI (CI-AKI). AKI developing after contrast material administration is reversible in most cases, but its development may be associated with adverse outcomes [12]. (See "Contrast-associated and contrast-induced acute kidney injury: Clinical features, diagnosis, and management", section on 'Diagnosis'.)
This topic provides recommendations for the prevention of CI-AKI in patients expected to receive intravenous iodinated contrast material with computed tomography (CT) [13]. Other related topics describe:
●Prevention of CI-AKI in patients expected to receive intra-arterial iodinated contrast material for angiography (see "Prevention of contrast-associated acute kidney injury related to angiography")
●Diagnostic evaluation of patients in preparation for iodinated contrast material before referral for CT (see "Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography")
TERMINOLOGY — Acute kidney injury (AKI) that occurs shortly after administration of iodinated contrast may or may not be causally related to contrast material:
●"Post-contrast AKI" or "contrast-associated AKI" are broad terms that refer to AKI occurring shortly after administration of iodinated contrast and that may or may not be directly caused by the contrast material.
●"Contrast-induced AKI (CI-AKI)," previously called "contrast-induced nephropathy (CIN)," is a specific term that refers to the subset of post-contrast AKI that is thought to be causally linked to contrast material administration (although a causal linkage cannot be established with certainty in epidemiologic studies).
Intravascular iodinated contrast media have been considered nephrotoxic based in large part upon animal experiments and uncontrolled human studies [14,15]. However, because many of these older reports lacked comparable control groups that did not receive contrast material, their applicability to our understanding of CI-AKI is unclear. Large controlled studies have since suggested that many cases of AKI following contrast administration may in fact be related to coincident nephrotoxic exposures (eg, hypovolemia, cardiac dysfunction, infection) present at the time that contrast material was administered [15-26].
As a result of these larger studies, multiple authorities in the radiology and nephrology communities adopted alternate terms ("post-contrast AKI" and "contrast-associated AKI") to refer to any AKI that occurs shortly after administration of iodinated contrast material [27]. Such terms are agnostic to cause and include both CI-AKI as well as coincidental AKI. Since coincident AKI is so common, true CI-AKI is difficult to diagnose accurately in the context of a clinical study and generally requires a study design with a control arm not exposed to contrast material [14-25,27]. Thus, the term "CI-AKI" (or "CIN") should be reserved for AKI that can be causally linked to contrast material administration, while the terms "post-contrast AKI" and "contrast-associated AKI" should be used to reflect any AKI that develops shortly after contrast material exposure.
EPIDEMIOLOGY — The reported incidence of post-contrast acute kidney injury (AKI), broadly, and contrast-induced AKI (CI-AKI), specifically, varies widely depending upon the definition, the presence or absence of risk factors, the type of contrast used, the volume of contrast material administered, the route of administration, and the patient population examined. In the absence of risk factors, the incidence of CI-AKI is negligible.
Incidence — Large, retrospective, cohort studies that included high-risk patients receiving iodinated contrast material with computed tomography (CT) as well as an appropriate, propensity-matched control group reported that the incidence of post-contrast AKI was high, ranging from 12 to 50 percent [17,18,28-31]. Conversely, the incidence of CI-AKI in these studies was, overall, negligible. Several of these cohorts found no risk of CI-AKI, regardless of baseline chronic kidney disease (CKD), although others identified CI-AKI in patients with severely reduced estimated glomerular filtration rate (eGFR), specifically among those with eGFR <30 mL/min/1.73 m2 [17,18,28-30]. Conclusions from these studies can be summarized as follows:
●eGFR ≥45 mL/min/1.73 m2 – Among the general population of patients with eGFR ≥45 mL/min/1.73 m2, CI-AKI from intravenous iodinated contrast material administration generally does not occur.
●eGFR of 30 to 44 mL/min/1.73 m2 – There may be a small risk of CI-AKI in patients with eGFR of 30 to 44 mL/min/1.73 m2, but the exact incidence in this population is uncertain. In one large propensity-matched study, for example, the incidence of AKI in patients with this degree of baseline kidney dysfunction was 1 percent higher among those undergoing a contrast-enhanced CT compared with those undergoing an unenhanced CT (16 versus 15 percent) [29].
●eGFR <30 mL/min/1.73 m2 – The risk of CI-AKI in patients with eGFR <30 mL/min/1.73 m2 appears to be higher. In one large, propensity-matched study, post-contrast AKI developed in 35 percent of patients with baseline eGFR <30 mL/min/1.73 m2 who underwent contrast-enhanced CT and in 14 percent who underwent unenhanced CT [29].
Although these propensity-matched studies are the best available data to determine risk for AKI after intravenous contrast administration, they may be limited by the possibility of unmeasured confounders that could result in residual selection bias. An alternative explanation for the equivalent incidence of AKI among those receiving and not receiving iodinated contrast may be a higher risk of coincident AKI in control patients, which could obscure the contribution of contrast media to the AKI seen in contrast-exposed patients.
Risk factors — Factors that increase the risk of post-contrast AKI include [2,7,9,13,32-35]:
●Impaired kidney function prior to contrast material administration – Impairment of kidney function, whether due to CKD or an ongoing episode of AKI, is the primary risk factor for post-contrast AKI. (See 'Identifying high-risk patients' below.)
Among patients with CKD, risk of post-contrast AKI is higher among those with lower baseline eGFR and may be potentiated by diabetes mellitus [4,32]. In one study, for example, the incidence of post-contrast AKI in patients whose baseline serum creatinine was >1.5 mg/dL (133 mmol/L) was 33 percent in diabetic patients and 12 percent in nondiabetic patients [4]. Diabetes was not associated with an increased risk among those with baseline serum creatinine <1.5 mg/dL. However, other studies, while supporting an association between reduced baseline kidney function and higher risk of post-contrast AKI, failed to identify diabetes as an additive risk factor, regardless of baseline eGFR [29].
●Reduced kidney perfusion – Reduced kidney perfusion, which is often due to heart failure, hypovolemia, hemodynamic instability, or drugs that affect kidney hemodynamics, may be associated with a higher risk of post-contrast AKI. The association of these risk factors with post-contrast AKI has been observed in some, but not all, studies. The factors that reduce kidney perfusion may exacerbate the risk for post-contrast AKI or may be coincident to it [36].
●Type of contrast material – Use of high-osmolality contrast media (HOCM) is associated with an increased risk of post-contrast AKI compared with use of low-osmolality contrast media (LOCM) or iso-osmolality contrast media (IOCM) [4,5,11,33,37]. However, HOCM is no longer used in modern clinical practice for intravascular administration and is therefore no longer an important risk factor for CI-AKI.
In general, when given intravenously, there is no clinically important difference in risk of post-contrast AKI comparing IOCM with LOCM. However, iohexol (a specific LOCM) may be associated with a greater risk of post-contrast AKI compared with other LOCM. (See "Prevention of contrast-associated acute kidney injury related to angiography".)
Other potential risk factors have been identified for post-contrast AKI after intra-arterial administration of contrast material; these include the volume of contrast material, proteinuria, hyperglycemia, and use of renin-angiotensin-aldosterone system inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). Whether any of these are important risk factors for AKI after intravenous contrast administration is unclear. These potential risk factors are discussed elsewhere. (See "Prevention of contrast-associated acute kidney injury related to angiography".)
IDENTIFYING HIGH-RISK PATIENTS — The risk of contrast-induced acute kidney injury (CI-AKI) among patients referred for contrast-enhanced computed tomography (CT) primarily depends upon kidney function (algorithm 1) [4,6,9,11,13,32,33,38-40]. Patients with unknown kidney function should have an estimated glomerular filtration rate (eGFR) calculated if they have risk factors for kidney function impairment. The specific factors used to identify an at-risk patient and thereby justify kidney function screening vary depending upon how sensitive or specific a radiology practice wishes to be with respect to identifying high-risk patients [27]. Evaluation of a patient's kidney function in preparation for CT is described elsewhere. (See "Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography", section on 'Assessing risk for contrast-induced nephropathy'.)
Clinically important nephrotoxicity due to intravenous iodinated contrast material is uncommon in patients undergoing CT who are not at high risk for this complication. Patients who should receive preventive measures are those who do not have contraindications for prophylaxis and who meet one of the following criteria (algorithm 1):
●Stable eGFR <30 mL/min/1.73 m2 and not on dialysis.
●Ongoing episode of AKI.
●In addition, some (but not all) experts prescribe prophylaxis for select patients with stable eGFR 30 to 44 mL/min/1.73 m2 who are not on dialysis but who have multiple other potential risk factors. (See 'Risk factors' above.)
In general, patients with a stable eGFR ≥30 mL/min/1.73 m2, patients on dialysis, and patients who require an emergency CT to diagnose a life-threatening condition do not require preventive measures. (See "Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography", section on 'Patients with impaired kidney function'.)
Occasionally, clinical care providers may choose to pursue prophylactic measures in patients with eGFR 30 to 44 mL/min/1.73 m2 who have multiple risk factors for post-contrast AKI (see 'Risk factors' above). Although observational studies failed to identify a significantly increased incidence of CI-AKI in this group of patients, the impact of multiple risk factors (eg, proteinuria, diabetes, heart failure) have not been well studied. Thus, it is possible that patients with multiple concomitant risk factors may be at risk of CI-AKI, even if the larger cohort is not. If there is uncertainty about the risks and benefits of performing an unenhanced or enhanced CT scan in a specific patient, the ordering provider can contact the radiologist to clarify. As with any procedure, a full discussion of the risks and benefits should be discussed with the patient by the ordering provider.
PREVENTION AMONG HIGH-RISK PATIENTS
Our approach — For patients at high risk for acute kidney injury (AKI) after intravenous contrast material administration with computed tomography (CT) (algorithm 1), we take the following approach (see 'Identifying high-risk patients' above):
●Verify that iodinated contrast material is necessary. If an alternative test is likely to provide an accurate and reliable diagnosis, we proceed without administering contrast material. (See 'Verify that contrast material is necessary' below.)
●Among euvolemic and hypovolemic inpatients, and emergency department patients whose clinical course permits it, we administer intravenous isotonic saline. Hypervolemic patients and patients receiving dialysis in general are not given volume expansion. There are no established dosing, duration, or injection rate recommendations for how the saline should be administered. Commonly used regimens are presented below. (See 'Inpatients and those in the emergency department' below.)
In high-risk outpatients, we prefer volume expansion with intravenous isotonic saline, if feasible, similar to our approach among inpatients. However, outpatients are sometimes given oral hydration [41]. There are no established dosing or timing recommendations for how the oral hydration should be administered. Some encourage patient-directed oral hydration before and after the scan (eg, total one to two liters). (See 'Outpatients' below.)
●Use low- or iso-osmolar contrast agents. Use of these agents is standard for all diagnostic imaging examinations. (See "Prevention of contrast-associated acute kidney injury related to angiography", section on 'Dose and type of contrast agent'.)
●If a patient at high risk for contrast-induced AKI (CI-AKI) is taking a metformin-containing medication, it should be discontinued for a minimum of 48 hours after the procedure and, if AKI develops, not reinstated until the kidney function has improved. In addition, metformin should generally be avoided in patients with estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2. (See 'Withdrawal of metformin and nephrotoxic drugs in high-risk patients' below.)
If a patient is taking noncritical nephrotoxic medications, these should generally be withheld for 48 hours after administration of contrast material at the discretion of the ordering clinician and, if AKI develops, not resumed until the kidney function has improved.
For patients who are not at high risk for AKI after contrast-enhanced CT, we verify the need for contrast material; however, we do not prescribe prophylactic measures, do not withdraw nephrotoxic medications, and do not suspend metformin.
Verify that contrast material is necessary — The indications for contrast material administration should be reviewed for all patients, particularly those considered high risk for CI-AKI. Alternative tests might include, for example, noncontrast CT, ultrasound, or magnetic resonance imaging. Imaging alternatives for many common clinical scenarios are discussed in the relevant UpToDate topics or in the American College of Radiology (ACR) Appropriateness Criteria [42]. A discussion with a radiologist is likely to be helpful in high-risk patients.
Volume expansion — We generally prescribe volume expansion in patients who are at high risk for CI-AKI, unless they are hypervolemic or are receiving dialysis. Determining whether a patient is at high risk for CI-AKI after CT is presented above (algorithm 1). (See 'Identifying high-risk patients' above.)
In general, patients without known AKI and with eGFR ≥30 mL/min/1.73 m2 do not require prophylactic measures [43]. In some circumstances (ie, patients with multiple potential risk factors and eGFR 30 to 44 mL/min/1.73 m2), the ordering provider may elect to administer prophylaxis, although such an approach is based upon indirect data from populations receiving intra-arterial (rather than intravenous) contrast.
Intravenous volume administration is commonly used in high-risk patients (AKI or eGFR <30 mL/min/1.73 m2 and not receiving dialysis) who require contrast-enhanced CT despite an absence of adequately designed randomized trials demonstrating benefit and observational evidence that a benefit is lacking [44,45]. However, indirect evidence from several trials of such patients undergoing coronary angiography (rather than intravenous contrast administration) found a benefit from intravenous saline versus either oral hydration or no saline for the prevention of post-contrast AKI. (See "Prevention of contrast-associated acute kidney injury related to angiography".)
Three trials have enrolled patients with chronic kidney disease (CKD) who were undergoing intravenous contrast material administration (rather than intra-arterial contrast material) for CT. However, none included patients who had eGFR <30 mL/min/1.73 m2 or AKI, and none found evidence of benefit from prophylactic intravenous fluid administration [43,46]:
●A single-center, randomized trial (A MAstricht Contrast-Induced Nephropathy Guidelines Study [AMACING]) found similar rates of post-contrast AKI (defined as a 25 percent or greater increase in plasma creatinine) among 660 patients with stage IIIa (eGFR 45 to 59 mL/min/1.73 m2) or stage IIIb (eGFR 30 to 45 mL/min/1.73 m2) CKD who were assigned to receive prophylactic intravenous isotonic saline or no intravenous fluids. Approximately one-half of the patients underwent procedures for which intravenous contrast material was given [43]. Prophylactic volume expansion did not reduce the incidence of AKI (2.7 versus 2.6 percent). Adverse events including heart failure, hyponatremia, and arrhythmia were more common in the group receiving intravenous fluid (5.5 versus 0 percent). However, this trial has some potentially important limitations [47]. These include a lower-than-expected incidence of post-contrast AKI (ie, 2.6 percent), which may have been due to the fact that no patients had an eGFR <30 mL/min/1.73 m2 and only one-third had an eGFR 30 to 44 mL/min/1.73 m2). In addition, 35 percent of the population had a postprocedure serum creatinine level obtained five or six days after contrast material exposure, and therefore some cases of post-contrast AKI may have been missed.
●In another trial of 139 patients with mild to moderate CKD who were undergoing CT pulmonary angiography, no prophylaxis was compared with a 250 mL intravenous bolus of sodium bicarbonate [46]. The incidence of post-contrast AKI was similar in both groups (7 versus 9 percent). In a similar trial of 554 patients with mild to moderate CKD, post-contrast AKI occurred at similar rates among those receiving, and not receiving, a 250 mL intravenous bolus of sodium bicarbonate (2.7 versus 3.1 percent) [48].
Each of these trials were limited by the small number of events and the fact that enrolled patients were not at high risk for CI-AKI after CT. This is relevant because high-risk patients are the only patients for whom prophylaxis is indicated.
Inpatients and those in the emergency department — Among euvolemic and hypovolemic inpatients, and emergency department patients whose clinical course permits it, we administer intravenous isotonic saline. Hypervolemic patients and patients receiving dialysis in general are not given volume expansion. There are no established dosing, duration, or injection rate recommendations for how the saline should be administered. Some commonly used intravenous regimens for inpatients and emergency department patients include (time permitting):
●3 mL/kg for one hour preprocedure, and 1.5 mL/kg/hour during and four to six hours postprocedure (total postprocedure volume at least 6 mL/kg)
●1 mL/kg/hour for 6 to 12 hours preprocedure, and 1 mL/kg/hour during and 6 to 12 hours postprocedure
When intravenous volume expansion is indicated, we use isotonic saline rather than a sodium bicarbonate-based infusion [49]. Although several trials suggested equivalent or better outcomes with sodium bicarbonate [49-65], a large, high-quality, randomized trial of 5177 adults undergoing angiography found no benefit of bicarbonate compared with normal saline [49]. In addition, isotonic saline is commercially available and is less expensive than bicarbonate, and there is no risk of compounding errors [45].
Outpatients — In outpatients at high risk for CI-AKI, we prefer intravenous isotonic saline prophylaxis using a regimen that is similar to the options described for inpatients. (See 'Inpatients and those in the emergency department' above.)
However, some clinicians and practices prescribe oral hydration rather than intravenous volume expansion in such patients [41]. There are no established dosing or timing recommendations for oral hydration; some encourage patient-directed oral hydration before and after the scan (eg, total one to two liters).
Low- or iso-osmolality contrast — In general, only low-osmolality contrast media (LOCM) and iso-osmolality contrast media (IOCM) are used for modern intravascular administrations. High-osmolality contrast media (HOCM) is no longer used due to a higher side effect profile. The type of contrast material used for a CT is typically determined by the hospital or radiology department and is not selected by the referring provider. (See "Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography", section on 'Types of contrast material'.)
Iodinated contrast media are either ionic or nonionic and of variable osmolality [10,66]. LOCM have an osmolality of approximately 600 mOsm/kg. IOCM have an osmolality of approximately 300 mOsm/kg.
The choice between LOCM and IOCM for contrast-enhanced CT does not appear to substantially affect the risk of post-contrast AKI. As an example, in one meta-analysis of six randomized trials, intravenous administration of iodixanol (IOCM) failed to reduce the rate of post-contrast AKI compared with LOCM (pooled relative risk 0.84, 95% CI 0.42-1.71) [67]. In addition, there was no benefit on the need for kidney replacement therapy, cardiovascular outcomes, or death. A separate meta-analysis reached generally similar conclusions [68], although one particular LOCM (iohexol) was associated with a higher risk compared with IOCM.
Our approach is broadly consistent with guidelines from the ACR, the American College of Cardiology/American Heart Association (ACC/AHA), and Kidney Disease: Improving Global Outcomes (KDIGO) committee [45,69,70].
Withdrawal of metformin and nephrotoxic drugs in high-risk patients — In patients deemed to be at high risk for CI-AKI who are taking metformin and who are to undergo CT with administration of iodinated contrast material, we agree with the 2018 ACR guidelines that the drug should be temporarily discontinued at the time of, or prior to, the study and should be withheld for at least 48 hours. (See 'Identifying high-risk patients' above.)
Metformin should not be resumed until the kidney function has been reassessed by the ordering provider and found to be acceptable. In addition, metformin should generally be avoided in patients with eGFR <30 mL/min/1.73 m2. (See "Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Contraindications'.)
We also agree with the 2018 ACR guidelines that, among patients who are not high risk, there is no need to discontinue metformin.
Our approach differs from the original metformin package inserts approved by the US Food and Drug Administration (FDA), which state that metformin should be withheld temporarily for all patients undergoing imaging using intravenous iodinated contrast media. The rationale was that, if AKI were to develop due to contrast media, an accumulation of metformin could occur and result in lactic acidosis. However, that risk is believed to be negligible for patients not at high risk. (See "Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Lactic acidosis'.)
Our approach also differs from the 2016 US FDA labeling that recommended discontinuation of metformin in patients with an eGFR between 30 and 60 mL/min/1.73 m2.
Patients taking metformin are not at higher risk than other patients for CI-AKI [70,71]. In addition, among patients who are not at high risk for CI-AKI after CT, metformin does not need to be discontinued either prior to or following contrast material administration, and there is no need to reassess the patient's kidney function following the test or procedure.
Contrast dose — A dose-toxicity relationship following intravenous administration has not been observed as it has been for cardiac angiography. Additionally, the dose-toxicity relationship observed following cardiac angiography is a correlative one; patients are not randomly assigned to get higher or lower doses in such studies, limiting conclusions about dose toxicity. As an example, patients necessitating higher contrast material volumes may have a higher risk for post-contrast AKI. Separating patient and disease factors from contrast material-related factors is therefore complicated.
The contrast material dose given for a particular CT examination should be based upon what is necessary to obtain a reliable diagnostic examination. The contrast material dose should not be lowered ad hoc in high-risk patients for fear of AKI; otherwise, there is a risk of a nondiagnostic scan in addition to any potential risk from the contrast material.
If multiple doses of contrast material are indicated, there is no specific cumulative dose threshold above which contrast material should be delayed or withheld. In high-risk patients, if multiple sequential administrations are needed, judgment should be exercised with respect to the timing of the examinations and the clinical need for a timely diagnosis.
Other preventive measures we do not use — A variety of other measures have been attempted to reduce the risk of post-contrast AKI. Generally speaking, these are unproven and not recommended. (See "Prevention of contrast-associated acute kidney injury related to angiography".)
Prophylactic hemofiltration and hemodialysis — Prophylactic hemofiltration and hemodialysis are not indicated for the prevention of post-contrast AKI or CI-AKI. A 2012 meta-analysis that included eight studies of hemodialysis and three studies of hemofiltration/hemodiafiltration showed no benefit from these modalities on the incidence of post-contrast AKI [72].
In addition, prophylactic dialysis is not indicated for the prevention of volume overload or osmotic-induced electrolyte shifts from intravascular contrast material administration in most dialysis-dependent patients [73,74]. Similarly, there is no need for immediate dialysis after contrast material administration in order to preserve residual kidney function or to limit the risk of allergic-like reaction in hemodialysis patients [73,75-77]. Dialysis can typically wait until the next scheduled dialysis treatment.
Guided fluid repletion — Volume expansion strategies are listed above. (See 'Volume expansion' above.)
More invasive or elaborate means, such as measuring left ventricular end-diastolic pressure or use of the RenalGuard system (which replaces diuretic-induced urine output in real time with infusion of isotonic saline) are not indicated for the prevention of post-contrast AKI or CI-AKI related to intravenous administration.
Other measures — Other measures that lack evidence of efficacy to prevent post-contrast AKI in patients undergoing CT, and that we do not use, include acetylcysteine, remote ischemic preconditioning, withholding angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), statins, diuretics, oral sodium citrate, atrial natriuretic peptide, ascorbic acid, trimetazidine, and inhibitors of vasoconstriction (eg, fenoldopam).
SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Chronic kidney disease in adults".)
SUMMARY AND RECOMMENDATIONS
●Definitions – Acute kidney injury (AKI) that occurs shortly after administration of iodinated contrast material may or may not be causally related to the contrast material:
•"Post-contrast AKI" or "contrast-associated AKI" are broad terms that refer to AKI occurring shortly after administration of iodinated contrast and that may or may not be directly caused by the contrast material.
•"Contrast-induced AKI (CI-AKI)," previously called "contrast-induced nephropathy (CIN)," is a specific term that refers to the subset of post-contrast AKI that can be causally linked to contrast material administration.
●Epidemiology – The reported incidence of post-contrast AKI, broadly, and CI-AKI, specifically, varies widely depending upon the definition, the presence or absence of risk factors, the volume of contrast material administered, the route of administration, and the patient population examined. In the absence of risk factors, the incidence of CI-AKI is negligible. The primary risk factor is impairment of kidney function, whether due to chronic kidney disease (CKD) or an ongoing episode of AKI. Other potential risk factors may include diabetes mellitus, factors that reduce kidney perfusion (eg, heart failure, hypovolemia), proteinuria, and intra-arterial (rather than intravenous) contrast material administration. (See 'Epidemiology' above.)
●Risk stratification – The risk of CI-AKI among patients referred for computed tomography (CT) primarily depends upon kidney function (algorithm 1) [4,6,9,11,32,33,39]. Patients who should receive preventive measures are those who do not have contraindications for prophylaxis and who meet one of the following criteria (see 'Identifying high-risk patients' above):
•Stable estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 and not on dialysis.
•Ongoing episode of AKI.
•In addition, some (but not all) experts prescribe prophylaxis for select patients with stable eGFR 30 to 44 mL/min/1.73 m2 who are not on dialysis but who have multiple other potential risk factors. (See 'Risk factors' above.)
●Management of high-risk patients – For patients at high risk for AKI after intravenous contrast material administration with CT (algorithm 1), we take the following approach (see 'Identifying high-risk patients' above):
•Verify that iodinated contrast material is necessary. If an alternative test is likely to provide an accurate and reliable diagnosis, we proceed without administering contrast material. (See 'Verify that contrast material is necessary' above.)
•Among euvolemic and hypovolemic inpatients, and emergency department patients whose clinical course permits it, we suggest intravenous isotonic saline rather than oral hydration or no intravenous fluid administration (Grade 2C). Hypervolemic patients and patients receiving dialysis in general are not given volume expansion. (See 'Inpatients and those in the emergency department' above.)
Among outpatients at high risk for CI-AKI, we suggest intravenous fluid administration rather than no fluid administration (Grade 2C). Oral hydration is an alternative that is used by some clinicians. (See 'Outpatients' above.)
•Use low- or iso-osmolar contrast agents. Use of these agents is standard for intravascular administrations. (See "Prevention of contrast-associated acute kidney injury related to angiography", section on 'Dose and type of contrast agent'.)
•If a high-risk patient is taking a metformin-containing medication, it should be discontinued for a minimum of 48 hours after the procedure and, if AKI develops, not reinstated until the kidney function has improved. If a patient is taking noncritical nephrotoxic medications, these should generally be withheld at the discretion of the ordering provider for 48 hours after administration of contrast material and, if AKI develops, not resumed until the kidney function has improved. (See 'Withdrawal of metformin and nephrotoxic drugs in high-risk patients' above.)
●Interventions not recommended – A variety of other measures have been attempted to reduce the risk of post-contrast AKI. Generally speaking, these are unproven and not recommended. These include prophylactic hemofiltration and hemodialysis, guided fluid repletion, acetylcysteine, remote ischemic preconditioning withholding angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), statins, diuretics, oral sodium citrate, atrial natriuretic peptide, ascorbic acid, trimetazidine, and inhibitors of vasoconstriction (eg, fenoldopam). (See "Prevention of contrast-associated acute kidney injury related to angiography".)
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟